 |
市場調查報告書
商品編碼
1532575
HbA1c 檢測市場，按類型（實驗室檢測、即時檢測）、技術（免疫測定、色譜、硼酸親和色譜、HPLC）、最終用途（醫院、診斷實驗室、家庭護理）-預測（2024 年- 2032 年） ）HbA1c Testing Market, By Type (Laboratory-based Testing, Point-of-Care Testing), Technology (Immunoassays, Chromatography, Boronate Affinity Chromatography, HPLC), End-use (Hospital, Diagnostic Labs, Homecare) -Forecast (2024 - 2032) |
||||||
在糖尿病盛行率上升的推動下，HbA1c 檢測市場規模在 2024 年至 2032 年期間將以 8.6% 的速度擴大。根據國際糖尿病聯盟的數據，2021 年，有 5.37 億成年人（約十分之一）患有糖尿病。預計這一數字將大幅增加，到2030 年將達到6.43 億，到2045 年將達到7.83 億。有效糖尿病管理工具的需求激增。 HbA1c 測試可測量長期血糖水平，對於監測和管理糖尿病以及預防其併發症至關重要。
隨著各國投資升級和擴大醫療設施，糖尿病診斷服務的可近性和品質正在提高。最先進設備的可用性增加和醫療保健服務系統的改進有助於更有效和更廣泛的 HbA1c 檢測。
HbA1c 檢測產業根據類型、技術、最終用途和地區進行分類。
到 2032 年，基於實驗室的檢測領域將快速成長，因為它們因其高精度和可靠性而被認為是 HbA1c 測量的黃金標準。這些測試利用高效液相層析 (HPLC) 和免疫測定等先進技術來提供精確的結果，這對於有效的糖尿病管理至關重要。基於實驗室的測試的穩健性，以及處理大量患者和提供全面診斷資訊的能力，使其成為醫療機構的首選。
到 2032 年，家庭護理領域將出現可觀的成長。家庭護理測試設備的便利性使個人能夠定期追蹤他們的血糖水平，這對於有效的糖尿病管理至關重要。家庭測試技術的創新，例如方便用戶使用的血糖儀和 HbA1c 家庭測試套件，使患者能夠更輕鬆地進行測試並獲得可靠的結果，而無需經常前往醫療機構。
在該地區完善的醫療基礎設施以及人們對糖尿病及其管理的高度認知的推動下，歐洲 HbA1c 檢測行業規模將在 2032 年之前穩步擴大。歐洲國家正在投資先進的診斷技術並加強醫療保健服務，以改善糖尿病照護。此外，旨在增加糖尿病篩檢和早期檢測的政府措施和醫療政策也有助於市場擴張。
目錄
第 1 章：方法與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業影響力
- 成長動力
- 糖尿病盛行率增加
- 技術進步
- 開發新穎的測試方法
- 產業陷阱與挑戰
- 設備成本高
- 嚴格的監理政策
- 成長動力
- 成長潛力分析
- 技術景觀
- 監管環境
- 波特的分析
- PESTEL分析
第 4 章：競爭格局
- 介紹
- 公司矩陣分析
- 公司市佔率分析
- 戰略展望矩陣
第 5 章：市場估計與預測：按類型，2021 - 2032
- 主要趨勢
- 基於實驗室的測試
- 即時護理 (POC) 測試
第 6 章：市場估計與預測：按技術分類，2021 - 2032 年
- 主要趨勢
- 免疫測定
- 色譜法
- 酵素法檢測
- 硼酸鹽親和層析
- 高效液相層析法
- 其他技術
第 7 章：市場估計與預測：按最終用途，2021 - 2032 年
- 主要趨勢
- 醫院和診所
- 診斷實驗室
- 家庭護理設置
- 其他最終用戶
第 8 章：市場估計與預測：按地區，2021 - 2032
- 主要趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
- 亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
- 中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
第 9 章：公司簡介
- Abbott Laboratories
- ARKRAY, Inc.
- Bio-Rad Laboratories, Inc.
- Ceragem Medisys Inc.
- Danaher Corporation
- EKF Diagnostics
- F. Hoffmann-La Roche Ltd.
- HUMAN
- Menarini Diagnostics s.r.l
- PTS Diagnostics
- Randox Laboratories Ltd.
- SAKAE CO. LTD.
- SEKISUI MEDICAL CO., LTD.
- Siemens Healthineers AG
- Trinity Biotech plc
The HbA1c Testing Market size will expand at 8.6% rate during 2024-2032, driven by the rising prevalence of diabetes. According to Internation Diabetes Federation, in 2021, 537 million adults, or approximately 1 in 10, were living with diabetes. This number is projected to increase significantly, reaching 643 million by 2030 and 783 million by 2045. With increasing rate of diabetes globally, driven by factors such as sedentary lifestyles, unhealthy diets, and aging populations, the demand for effective diabetes management tools is surging. HbA1c testing, which measures long-term blood glucose levels, is crucial for monitoring and managing diabetes and preventing its complications.
As countries invest in upgrading and expanding their healthcare facilities, the accessibility and quality of diabetes diagnostic services are improving. The increased availability of state-of-the-art equipment and improved healthcare delivery systems contribute to more efficient and widespread HbA1c testing.
The HbA1c testing industry is classified based on type, technology, end-use, and region.
The laboratory-based testing segment will grow rapidly through 2032, as they are considered the gold standard for HbA1c measurement due to their high accuracy and reliability. These tests utilize advanced techniques such as high-performance liquid chromatography (HPLC) and immunoassays to provide precise results, essential for effective diabetes management. The robustness of laboratory-based testing, along with its ability to handle high patient volumes and provide comprehensive diagnostic information, makes it a preferred choice for healthcare facilities.
The homecare segment will witness decent growth through 2032. With the increasing adoption of home monitoring devices, patients with diabetes are increasingly managing their HbA1c levels at home. The convenience of homecare testing devices allows individuals to track their glucose levels regularly, which is crucial for effective diabetes management. Innovations in home testing technologies, such as user-friendly glucose meters and HbA1c home testing kits, are making it easier for patients to perform tests and obtain reliable results without frequent visits to healthcare facilities.
Europe HbA1c testing industry size will expand at a steady pace through 2032, driven by the region's well-established healthcare infrastructure, coupled with high awareness levels about diabetes and its management. European countries are investing in advanced diagnostic technologies and enhancing healthcare services to improve diabetes care. Additionally, government initiatives and medical policies aimed at increasing diabetes screening and early detection are contributing to the market expansion.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360°synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of diabetes
- 3.2.1.2 Technological advancement
- 3.2.1.3 Development of novel testing methodologies
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 High cost of devices
- 3.2.2.2 Stringent regulatory policies
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Technological landscape
- 3.5 Regulatory landscape
- 3.6 Porter's analysis
- 3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Company market share analysis
- 4.4 Strategic outlook matrix
Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Laboratory-based testing
- 5.3 Point-of-care (POC) testing
Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Immunoassays
- 6.3 Chromatography
- 6.4 Enzymatic assays
- 6.5 Boronate affinity chromatography
- 6.6 High-performance liquid chromatography
- 6.7 Other technologies
Chapter 7 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Hospitals & clinics
- 7.3 Diagnostic laboratories
- 7.4 Homecare settings
- 7.5 Other end-users
Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
- 8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
- 9.1 Abbott Laboratories
- 9.2 ARKRAY, Inc.
- 9.3 Bio-Rad Laboratories, Inc.
- 9.4 Ceragem Medisys Inc.
- 9.5 Danaher Corporation
- 9.6 EKF Diagnostics
- 9.7 F. Hoffmann-La Roche Ltd.
- 9.8 HUMAN
- 9.9 Menarini Diagnostics s.r.l
- 9.10 PTS Diagnostics
- 9.11 Randox Laboratories Ltd.
- 9.12 SAKAE CO. LTD.
- 9.13 SEKISUI MEDICAL CO., LTD.
- 9.14 Siemens Healthineers AG
- 9.15 Trinity Biotech plc
